Prexasertib
- Generic Name
- Prexasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N7O2
- CAS Number
- 1234015-52-1
- Unique Ingredient Identifier
- 820NH671E6
- Background
Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, breast cancer, and Ovarian Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT04095221
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04023669
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03735446
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT03495323
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 172
- Registration Number
- NCT03414047
- Locations
- 🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States
🇬🇧Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
🇺🇸University of Southern Florida School of Medicine, Gainesville, Florida, United States
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Geoffrey Shapiro, MD, PhD
- Target Recruit Count
- 29
- Registration Number
- NCT03057145
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9
- Registration Number
- NCT02860780
- Locations
- 🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇩🇪For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT02808650
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT02778126
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Liverpool, United Kingdom
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 133
- Registration Number
- NCT02735980
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.